Ivabradine
- Generic Name
- Ivabradine
- Brand Names
- Corlanor, Lancora, Procoralan, Corlentor, Ivabradine Accord, Ivabradine Anpharm, Ivabradine Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C27H36N2O5
- CAS Number
- 155974-00-8
- Unique Ingredient Identifier
- 3H48L0LPZQ
- Background
Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats ...
- Indication
Ivabradine is indicated by the FDA to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤35%, who are in sinus rhythm with resting heart rate ≥70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contrain...
- Associated Conditions
- Chronic Heart Failure (CHF), Chronic Stable Angina Pectoris, Left Ventricular Dysfunction, Chronic, stable, symptomatic Heart Failure
- Associated Therapies
- -
Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Phillip Levy
- Target Recruit Count
- 132
- Registration Number
- NCT03168529
- Locations
- 🇺🇸
Wayne State University, Detroit, Michigan, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.
- Conditions
- Interventions
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 23
- Registration Number
- NCT03137537
- Locations
- 🇺🇸
Boston Children Hospital, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease
- Conditions
- Interventions
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
Pulse Reduction On Beta-blocker and Ivabradine Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 28
- Registration Number
- NCT02973594
- Locations
- 🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2019-10-01
- Lead Sponsor
- Duke University
- Target Recruit Count
- 104
- Registration Number
- NCT02827500
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Ohio State University- Davis Heart and Lung Research Institute, Columbus, Ohio, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease
- Conditions
- Interventions
- First Posted Date
- 2016-02-15
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Campus Bio-Medico University
- Target Recruit Count
- 70
- Registration Number
- NCT02681978
- Locations
- 🇮🇹
Campus Bio-Medico University, Rome, RM, Italy
To Assess the Anti-anginal Safety and Efficacy of Ivabradine in Subjects With Stable，Symptomatic Chronic Angina
- First Posted Date
- 2015-12-07
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Xintong Pharmacy Company
- Target Recruit Count
- 336
- Registration Number
- NCT02623569
- Locations
- 🇨🇳
Zhongda Hospital Southeast University, Nanjing, Jiangsu, China
🇨🇳The General Hospital of Shenyang Military, Shenyang, Liaoning, China
🇨🇳Guizhou Provincial People's Hospital, Guiyang, Guizhou, China
Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)
- Conditions
- Interventions
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- University Hospital, Rouen
- Target Recruit Count
- 30
- Registration Number
- NCT02584439
- Locations
- 🇫🇷
Department of Pharmacology, Rouen university Hospital, Rouen, France
Ivabradine and Post-revascularisation Microcirculatory Dysfunction
- Locations
- 🇬🇧
Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Institut de Recherches Internationales Servier
- Target Recruit Count
- 19102
- Registration Number
- NCT02446990
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy
🇬🇧Royal Brompton Hospital, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.